Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

F. Hoffman-La Roche LTD - What, why and how: Expert review and opinions on the potential of oral SERDs for our patients with HR+ BC

What have we seen from oral SERDs and what could they mean for our patients in future?

Date

12 Sep 2022

Session

F. Hoffman-La Roche LTD - What, why and how: Expert review and opinions on the potential of oral SERDs for our patients with HR+ BC

Topics

Endocrine Therapy

Tumour Site

Breast Cancer

Presenters

Aditya Bardia

Authors

A. Bardia

Author affiliations

  • Medical Oncology Dept., Massachusetts General Hospital Cancer Center, Harvard Medical School, 02114 - Boston/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.